Literature DB >> 1967223

Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents.

A Kiue1, T Sano, K Suzuki, H Inada, M Okumura, J Kikuchi, S Sato, K Kohno, M Kuwano.   

Abstract

Newly synthesized 1,4-dihydropyridine derivatives (NK-compounds) were screened to determine whether they could overcome vincristine (VCR) resistance in VCR-resistant (P388/VCR) leukemia-bearing mice. Among the 57 NK-compounds examined, six compounds had strong reversing ability (Grade A), 18 partially overcame the resistance (Grade B), and 33 did not reverse the resistance (Grade C). The ability to overcome resistance varied considerably with the nature of substituents at positions 3.5 of the 1,4-dihydropyridine, and the most suitable substituents were the pyridylalkyl-including esters. Calcium antagonistic activity of NK-compounds having pyridylalkyl-including esters at positions 3.5 and dithiene ring at position 4 of the 1,4-dihydropyridine was greater than in those compounds having the dioxene ring at position 4. NK-242, which was assessed at Grade A and had no calcium antagonistic activity, improved therapeutic effects in both VCR-sensitive (P388/S) leukemia- and P388/VCR leukemia-bearing mice when combined with VCR. Fourteen NK-compounds were screened to determine whether they could inhibit photoaffinity labeling of the P-glycoprotein (Mr 170,000 glycoprotein) in a multidrug-resistant cell line by [3H]azidopine. All six compounds of Grade A and two of the three compounds of Grade B almost completely inhibited the labeling of Mr 170,000 glycoprotein at 1 to 10 microM. Thus there was a good correlation between the ability to reverse VCR resistance in vivo and the inhibition of photoaffinity labeling of Mr 170,000 glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967223

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Reversal of multidrug resistance by phenothiazines and structurally related compounds.

Authors:  A Ramu; N Ramu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Fluorescent dye rhodamine 6G as a molecular probe to study drug resistance of C6 rat glioma cells.

Authors:  Y Matsumoto; N Sasaoka; T Tsuchida; T Fujiwara; S Nagao; T Ohmoto
Journal:  J Neurooncol       Date:  1992-07       Impact factor: 4.130

3.  Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice.

Authors:  A Kiue; T Sano; A Naito; M Okumura; K Kohno; M Kuwano
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

4.  Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.

Authors:  T Abe; K Koike; T Ohga; T Kubo; M Wada; K Kohno; T Mori; K Hidaka; M Kuwano
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

5.  Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.

Authors:  S Hasegawa; T Abe; S Naito; S Kotoh; J Kumazawa; D R Hipfner; R G Deeley; S P Cole; M Kuwano
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

6.  Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro.

Authors:  A Kiue; T Sano; A Naito; H Inada; K Suzuki; M Okumura; J Kikuchi; S Sato; H Takano; K Kohno
Journal:  Jpn J Cancer Res       Date:  1990-10

7.  ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice.

Authors:  H Arakawa; T Iguchi; T Yoshinari; K Kojiri; H Suda; A Okura
Journal:  Jpn J Cancer Res       Date:  1993-05

8.  Potentiation of the vincristine effect on P388 mouse leukemia cells by a newly synthesized dihydropyridine analogue, PAK-200.

Authors:  N Shudo; R Fujii; T Matsumoto; T Mizoguchi; K Seto; R Sakoda; S Akiyama
Journal:  Jpn J Cancer Res       Date:  1992-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.